Juno's Expert Pegs Patent License Value At $752M In Kite Trial
An economist hired by Sloan Kettering and Juno Therapeutics told a California jury Monday that defendant Kite Pharma would have paid $752 million to license the cancer immunotherapy patent it's accused...To view the full article, register now.
Already a subscriber? Click here to view full article